Related Experiment Videos
Ciprofloxacin: comparative data in cystic fibrosis
The American Journal of Medicine
|April 27, 1987
Summary
Oral ciprofloxacin offers a cost-effective treatment for cystic fibrosis patients battling Pseudomonas aeruginosa. This study found similar clinical and microbiologic outcomes compared to intravenous antibiotics, with no resistance observed in most patients.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pulmonology
Background:
- Cystic fibrosis (CF) patients frequently require anti-pseudomonal antibiotics.
- Pseudomonas aeruginosa is a common pathogen in CF, necessitating effective treatments.
- Oral antibiotic administration could improve cost-efficiency and patient management in CF.
Purpose of the Study:
- To evaluate the efficacy and safety of oral ciprofloxacin in treating P. aeruginosa infections in cystic fibrosis patients.
- To compare oral ciprofloxacin therapy with conventional intravenous antibiotic regimens.
Main Methods:
- 11 adult CF patients received oral ciprofloxacin (750 mg BID) for 2-8 weeks.
- A 13-year-old patient received 500 mg BID.
- Serum concentrations were monitored.
- Results were compared to a control group receiving intravenous tobramycin and azlocillin.
Main Results:
- Ciprofloxacin demonstrated broad activity against P. aeruginosa, with MICs ranging from 0.05 to 1.56 µg/ml.
- Clinical and microbiologic outcomes were comparable to intravenous therapy.
- One patient with Pseudomonas cepacia developed resistance; no other resistant strains emerged.
Conclusions:
- Oral ciprofloxacin is a viable and potentially cost-effective alternative for managing P. aeruginosa in CF patients.
- Further research is warranted, especially regarding P. cepacia infections and resistance development.